📊 HOTH Key Takeaways
Is HOTH a Good Investment? Thesis Analysis
Hoth Therapeutics exhibits severe fundamental deterioration with net income declining 52.3% YoY to -$12.5M despite $1.2B in revenue, indicating severe profitability challenges. The company is burning $9.8M in operating cash annually against only $6.2M in cash reserves, creating critical liquidity pressure with less than 1 year of runway. Negative returns (ROE -202.7%, ROA -164%) and worsening trends suggest fundamental business model distress with no clear path to profitability.
Why Buy HOTH? Key Strengths
- Zero long-term debt provides balance sheet flexibility
- Current ratio of 4.72x indicates strong immediate liquidity position
- Minimal capital expenditure requirements suggest asset-light operations
HOTH Investment Risks to Consider
- Severe cash burn of $9.8M annually against $6.2M cash reserves creates critical runway crisis
- Net income deteriorating 52.3% YoY signals accelerating fundamental weakness
- Massive negative returns on equity (-202.7%) and assets (-164%) indicate value destruction
- Revenue-to-profitability disconnect suggests accounting anomalies or non-recurring items masking core business weakness
- No insider activity in 90 days may reflect lack of confidence in recovery
Key Metrics to Watch
- Cash burn rate trend and remaining cash runway
- Operating cash flow sustainability and path to cash flow breakeven
- Revenue quality and recurring vs. non-recurring revenue composition
- Quarterly profitability trajectory and gross margin expansion
HOTH Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 4.72x current ratio provides a solid financial cushion.
HOTH Profitability Ratios
HOTH vs Healthcare Sector
How Hoth Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HOTH Overvalued or Undervalued?
Based on fundamental analysis, Hoth Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HOTH Balance Sheet & Liquidity
HOTH 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Hoth Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-1.28 indicates the company is currently unprofitable.
HOTH Growth Metrics (YoY)
HOTH Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $1.2B | -$1.6M | $-0.31 |
| Q2 2024 | $1.2B | -$1.6M | $-0.24 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HOTH Capital Allocation
HOTH SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Hoth Therapeutics, Inc. (CIK: 0001711786)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HOTH
What is the AI rating for HOTH?
Hoth Therapeutics, Inc. (HOTH) has an AI rating of STRONG SELL with 88% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HOTH's key strengths?
Claude: Zero long-term debt provides balance sheet flexibility. Current ratio of 4.72x indicates strong immediate liquidity position.
What are the risks of investing in HOTH?
Claude: Severe cash burn of $9.8M annually against $6.2M cash reserves creates critical runway crisis. Net income deteriorating 52.3% YoY signals accelerating fundamental weakness.
What is HOTH's revenue and growth?
Hoth Therapeutics, Inc. reported revenue of $1.2B.
Does HOTH pay dividends?
Hoth Therapeutics, Inc. does not currently pay dividends.
Where can I find HOTH SEC filings?
Official SEC filings for Hoth Therapeutics, Inc. (CIK: 0001711786) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HOTH's EPS?
Hoth Therapeutics, Inc. has a diluted EPS of $-0.90.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HOTH a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Hoth Therapeutics, Inc. has a STRONG SELL rating with 88% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HOTH stock overvalued or undervalued?
Valuation metrics for HOTH: ROE of -202.7% (sector avg: 15%), net margin of -1.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HOTH stock in 2026?
Our dual AI analysis gives Hoth Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HOTH's free cash flow?
Hoth Therapeutics, Inc.'s operating cash flow is $-9.8M, with capital expenditures of $3.7K. FCF margin is -0.8%.
How does HOTH compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1.0% (avg: 12%), ROE -202.7% (avg: 15%), current ratio 4.72 (avg: 2).